Klingman & Associates LLC Boosts Holdings in Eli Lilly and Company $LLY

Key Points

• Klingman & Associates LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 18.3% during the 2nd quarter, now holding 2,232 shares valued at approximately $1.74 million.
• The company's earnings per share (EPS) for the last quarter were $6.31, exceeding analyst estimates by $0.72, with revenues reaching $15.56 billion.
• Analysts have issued ratings for Eli Lilly, including a recent upgrade to "buy" from Erste Group Bank and a revised price target of $900 set by Deutsche Bank, showing a consensus target price of $938.61.

Klingman & Associates LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 18.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,232 shares of the company's stock after buying an additional 346 shares during the quarter. Klingman & Associates LLC's holdings in Eli Lilly and Company were worth $1,740,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Precedent Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in shares of Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after purchasing an additional 429 shares in the last quarter. Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $54,000. Duquesne Family Office LLC lifted its stake in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Finally, Corient IA LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $570,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $808.88 on Tuesday. The business's 50 day moving average is $756.56 and its two-hundred day moving average is $766.20. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The firm has a market cap of $765.57 billion, a price-to-earnings ratio of 52.87, a PEG ratio of 1.15 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research report on Friday, October 10th. Finally, DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $938.61.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.